Nivolumab
NCT03718767
National Cancer Institute · Phase 2 · Active, not recruiting · Enrollment 62
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
Nivolumab
National Cancer Institute · Phase 2 · Active, not recruiting · Enrollment 62
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.